World Health Organisation (WHO) continues successful collaboration with Paul-Ehrlich-Institut
Recommendation
12/13 May 2026
Regulatory Requirements and Practical Implementation
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
After eight years of successful collaboration as a "WHO Collaborating Centre for Quality Assurance of Blood Products and in vitro Diagnostic Devices" the World Health Organization (WHO) has confirmed that it will continue working with the Paul-Ehrlich-Institut (PEI) for another four years. The President of the Paul-Ehrlich Institut, Professor Klaus Cichutek, is proud that the institute is being recognised in this way: "PEI has achieved this thanks to its in-depth expertise in a wide range of areas connected with regulatory affairs and scientific research as well as its sustained and reliable support of the WHO’s activities". During his visit to the PEI on 1 July 2013, Daniel Bahr, the German Federal Minister of Health, confirmed that "The quality of the PEI's work is very highly appreciated by the WHO."
More details can be found in the PEI's press release entitled "World Health Organization (WHO) continues successful collaboration with Paul-Ehrlich-Institut".
Related GMP News
22.04.2026What are the GMP Requirements for ATMPs?
25.03.2026What are the GMP Requirements for Biotechnological Products?
18.03.2026Latest FDA Updates: Biosimilar Development Guidance
18.03.2026ECA ATMP Group publishes position paper on specifications considering patient-centricity
11.12.2025Utility of Comparative Efficacy Studies in Biosimilar Development
03.09.2025Standardisation of Monoclonal Antibodies (mAbs) by the EPC